Orphanet Journal of Rare Diseases (Sep 2023)

Health-related quality of life in a european sample of adults with early-treated classical PKU

  • Stephanie Maissen-Abgottspon,
  • Raphaela Muri,
  • Michel Hochuli,
  • Péter Reismann,
  • András Gellért Barta,
  • Ismail Mucahit Alptekin,
  • Álvaro Hermida-Ameijeiras,
  • Alessandro P. Burlina,
  • Alberto B. Burlina,
  • Chiara Cazzorla,
  • Jessica Carretta,
  • Roman Trepp,
  • Regula Everts

DOI
https://doi.org/10.1186/s13023-023-02917-w
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Phenylketonuria (PKU) is a rare inborn error of metabolism affecting the catabolism of phenylalanine (Phe). To date, findings regarding health-related quality of life (HRQoL) in adults with early-treated classical PKU are discrepant. Moreover, little is known about metabolic, demographic, and cognitive factors associated with HRQoL. Hence, we aimed to investigate HRQoL and its association with demographic, metabolic, and cognitive characteristics in a large European sample of adults with early-treated classical PKU. Results This cross-sectional study included 124 adults with early-treated classical PKU from Hungary, Italy, Spain, Switzerland, and Turkey. All participants prospectively completed the PKU quality of life questionnaire (PKU-QoL), a questionnaire specifically designed to evaluate the impact of PKU and its treatment on HRQoL in individuals with PKU. In addition, information about Phe levels (concurrent and past year), demographic (age and sex), and cognitive variables (intelligence quotient, IQ) were collected. Most domains revealed little or no impact of PKU on HRQoL and more than three-quarters of the patients rated their health status as good, very good, or excellent. Nevertheless, some areas of concern for patients were identified. Patients were worried about the guilt that they experience if they do not adhere to the dietary protein restriction and they were most concerned about high Phe levels during pregnancy. Further, tiredness was the most affected symptom, and the supplements’ taste was considered a main issue for individuals with PKU. The overall impact of PKU on HRQoL was higher in women (U = 1315.5, p = .012) and in adults with a lower IQ (r s = − 0.448, p = .005). The overall impact of dietary protein restriction was higher in adults with higher concurrent Phe levels (r s = 0.272, p = .007) and higher Phe levels during the past year (r s = 0.280, p = .009). Conclusion The impact of PKU on most domains assessed in the PKU-QoL was considered to be low. These results likely reflect the successful implementation of the newborn screening resulting in the prevention of severe adverse long-term outcomes. However, a particular clinical focus should be given to patients with lower IQ, higher Phe levels, and women, as these variables were associated with a lower HRQoL.

Keywords